Skip to main content
Top
Published in: Endocrine Pathology 1/2019

01-03-2019 | Neuroendocrine Tumor

In Situ Hybridization Analysis of Long Non-coding RNAs MALAT1 and HOTAIR in Gastroenteropancreatic Neuroendocrine Neoplasms

Authors: Ying-Hsia Chu, Heather Hardin, Jens Eickhoff, Ricardo V. Lloyd

Published in: Endocrine Pathology | Issue 1/2019

Login to get access

Abstract

Recent studies suggest onco-regulatory roles for two long non-coding RNAs (lncRNAs), MALAT1 and HOTAIR, in various malignancies; however, these lncRNAs have not been previously examined in neuroendocrine neoplasms (NENs) of gastroenteropancreatic origins (GEP-NENs). In this study, we evaluated the expressions and prognostic significance of MALAT1 and HOTAIR in 83 cases of GEP-NENs (60 grade 1, 17 grade 2, and 6 grade 3 tumors) diagnosed during the years 2005–2017. Expression levels of MALAT1 and HOTAIR were digitally quantitated in assembled tissue microarray slides labeled by chromogenic in situ hybridization (ISH) using InForm 1.4.0 software. We found diffuse nuclear expression of both HOTAIR and MALAT1 in all primary tumors of GEP-NENs with variable intensities. By multivariate model which adjusted for age and histologic grade, high expression of HOTAIR was associated with lower presenting T and M stages and subsequent development of metastases (P < 0.05). MALAT1 expression was associated with presenting T stage and development of metastases (P < 0.05). In summary, MALAT1 and HOTAIR are commonly expressed in GEP-NENs. High expression of either lncRNA showed grade-independent associations with clinically less aggressive disease.
Literature
1.
go back to reference Ohike N, Adsay NV, La Rosa S, Volante M, Zamboni G. 2017. WHO Classification of Tumours of Endocrine Organs, 10 ed. WHO Press, World Health Organization, Geneva. Ohike N, Adsay NV, La Rosa S, Volante M, Zamboni G. 2017. WHO Classification of Tumours of Endocrine Organs, 10 ed. WHO Press, World Health Organization, Geneva.
2.
go back to reference Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P. 2016. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist 21:1191–1199.CrossRef Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P. 2016. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist 21:1191–1199.CrossRef
3.
go back to reference Oberg K. 2009. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes 16:72–78.CrossRef Oberg K. 2009. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes 16:72–78.CrossRef
4.
go back to reference Lewis MA, Yao JC. 2014. Molecular pathology and genetics of gastrointestinal neuroendocrine tumours. Current Opinion in Endocrinology, Diabetes and Obesity 21:22–27.CrossRef Lewis MA, Yao JC. 2014. Molecular pathology and genetics of gastrointestinal neuroendocrine tumours. Current Opinion in Endocrinology, Diabetes and Obesity 21:22–27.CrossRef
5.
go back to reference Amair-Pinedo F, Matos I, Sauri T, Hernando J, Capdevila J. 2017. The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Target Oncol 12:757–774.CrossRef Amair-Pinedo F, Matos I, Sauri T, Hernando J, Capdevila J. 2017. The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Target Oncol 12:757–774.CrossRef
6.
go back to reference Thorns C, Schurmann C, Gebauer N, et al. 2014. Global microRNA profiling of pancreatic neuroendocrine neoplasias. Anticancer Res 34:2249–2254.PubMed Thorns C, Schurmann C, Gebauer N, et al. 2014. Global microRNA profiling of pancreatic neuroendocrine neoplasias. Anticancer Res 34:2249–2254.PubMed
7.
go back to reference Malczewska A, Kidd M, Matar S, Kos-Kudla B, Modlin IM. 2018. A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors. Neuroendocrinology 107:73–90.CrossRef Malczewska A, Kidd M, Matar S, Kos-Kudla B, Modlin IM. 2018. A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors. Neuroendocrinology 107:73–90.CrossRef
8.
go back to reference Yoon JH, Abdelmohsen K, Gorospe M. 2013. Posttranscriptional gene regulation by long noncoding RNA. J Mol Biol 425:3723–3730.CrossRef Yoon JH, Abdelmohsen K, Gorospe M. 2013. Posttranscriptional gene regulation by long noncoding RNA. J Mol Biol 425:3723–3730.CrossRef
9.
go back to reference Rinn JL, Chang HY. 2012. Genome regulation by long noncoding RNAs. Annu Rev Biochem 81:145–166.CrossRef Rinn JL, Chang HY. 2012. Genome regulation by long noncoding RNAs. Annu Rev Biochem 81:145–166.CrossRef
10.
go back to reference Yang Y, Junjie P, Sanjun C, Ma Y. 2017. Long non-coding RNAs in Colorectal Cancer: Progression and Future Directions. J Cancer 8:3212–3225.CrossRef Yang Y, Junjie P, Sanjun C, Ma Y. 2017. Long non-coding RNAs in Colorectal Cancer: Progression and Future Directions. J Cancer 8:3212–3225.CrossRef
11.
go back to reference Modali SD, Parekh VI, Kebebew E, Agarwal SK. 2015. Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors. Mol Endocrinol 29:224–237.CrossRef Modali SD, Parekh VI, Kebebew E, Agarwal SK. 2015. Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors. Mol Endocrinol 29:224–237.CrossRef
12.
go back to reference Parekh VI, Modali SD, Desai SS, Agarwal SK. 2015. Consequence of Menin Deficiency in Mouse Adipocytes Derived by In Vitro Differentiation. Int J Endocrinol 2015:149826.CrossRef Parekh VI, Modali SD, Desai SS, Agarwal SK. 2015. Consequence of Menin Deficiency in Mouse Adipocytes Derived by In Vitro Differentiation. Int J Endocrinol 2015:149826.CrossRef
13.
go back to reference Wei YL, Hua J, Liu XY, Hua XM, Sun C, Bai JA, Tang QY 2018. LncNEN885 inhibits epithelial-mesenchymal transition by partially regulation of Wnt/beta-catenin signalling in gastroenteropancreatic neuroendocrine neoplasms. Cancer Sci 109:3139–3148.CrossRef Wei YL, Hua J, Liu XY, Hua XM, Sun C, Bai JA, Tang QY 2018. LncNEN885 inhibits epithelial-mesenchymal transition by partially regulation of Wnt/beta-catenin signalling in gastroenteropancreatic neuroendocrine neoplasms. Cancer Sci 109:3139–3148.CrossRef
14.
go back to reference Pang EJ, Yang R, Fu XB, Liu YF. 2015. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer. Tumour Biol 36:2403–2407.CrossRef Pang EJ, Yang R, Fu XB, Liu YF. 2015. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer. Tumour Biol 36:2403–2407.CrossRef
15.
go back to reference Zheng HT, Shi DB, Wang YW, Li XX, Xu Y, Tripathi P, Gu WL, Cai GX, Cai SJ 2014. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int J Clin Exp Pathol 7:3174–3181.PubMedPubMedCentral Zheng HT, Shi DB, Wang YW, Li XX, Xu Y, Tripathi P, Gu WL, Cai GX, Cai SJ 2014. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int J Clin Exp Pathol 7:3174–3181.PubMedPubMedCentral
16.
go back to reference Wu ZH, Wang XL, Tang HM, et al. 2014. Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. Oncol Rep 32:395–402.CrossRef Wu ZH, Wang XL, Tang HM, et al. 2014. Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. Oncol Rep 32:395–402.CrossRef
17.
go back to reference Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, Kim S, Safe S 2013. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 32:1616–1625.CrossRef Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, Kim S, Safe S 2013. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 32:1616–1625.CrossRef
18.
go back to reference Emadi-Andani E, Nikpour P, Emadi-Baygi M, Bidmeshkipour A. 2014. Association of HOTAIR expression in gastric carcinoma with invasion and distant metastasis. Adv Biomed Res 3:135.CrossRef Emadi-Andani E, Nikpour P, Emadi-Baygi M, Bidmeshkipour A. 2014. Association of HOTAIR expression in gastric carcinoma with invasion and distant metastasis. Adv Biomed Res 3:135.CrossRef
19.
go back to reference Ge XS, Ma HJ, Zheng XH, Ruan HL, Liao XY, Xue WQ, Chen YB, Zhang Y, Jia WH 2013. HOTAIR, a prognostic factor in esophageal squamous cell carcinoma, inhibits WIF-1 expression and activates Wnt pathway. Cancer Sci 104:1675–1682.CrossRef Ge XS, Ma HJ, Zheng XH, Ruan HL, Liao XY, Xue WQ, Chen YB, Zhang Y, Jia WH 2013. HOTAIR, a prognostic factor in esophageal squamous cell carcinoma, inhibits WIF-1 expression and activates Wnt pathway. Cancer Sci 104:1675–1682.CrossRef
21.
go back to reference Han Y, Wu Z, Wu T, Huang Y., Cheng Z., Li X., Sun T., Xie X., Zhou Y., du Z. 2016. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by downregulation of MMP2 and inactivation of ERK/MAPK signaling. Cell Death Dis 7:e2123.CrossRef Han Y, Wu Z, Wu T, Huang Y., Cheng Z., Li X., Sun T., Xie X., Zhou Y., du Z. 2016. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by downregulation of MMP2 and inactivation of ERK/MAPK signaling. Cell Death Dis 7:e2123.CrossRef
22.
go back to reference Cao S, Wang Y, Li J, Lv M, Niu H, Tian Y. 2016. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by suppressing miR-155 expression and activating FBXW7 function. Am J Cancer Res 6:2561–2574.PubMedPubMedCentral Cao S, Wang Y, Li J, Lv M, Niu H, Tian Y. 2016. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by suppressing miR-155 expression and activating FBXW7 function. Am J Cancer Res 6:2561–2574.PubMedPubMedCentral
23.
go back to reference Kim J, Piao HL, Kim BJ, Yao F, Han Z, Wang Y, Xiao Z, Siverly AN, Lawhon SE, Ton BN, Lee H, Zhou Z, Gan B, Nakagawa S, Ellis MJ, Liang H, Hung MC, You MJ, Sun Y, Ma L 2018. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet 50:1705–1715.CrossRef Kim J, Piao HL, Kim BJ, Yao F, Han Z, Wang Y, Xiao Z, Siverly AN, Lawhon SE, Ton BN, Lee H, Zhou Z, Gan B, Nakagawa S, Ellis MJ, Liang H, Hung MC, You MJ, Sun Y, Ma L 2018. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet 50:1705–1715.CrossRef
24.
go back to reference Zhao M, Wang S, Li Q, Ji Q, Guo P, Liu X. 2018. MALAT1: A long non-coding RNA highly associated with human cancers. Oncol Lett 16:19–26.PubMedPubMedCentral Zhao M, Wang S, Li Q, Ji Q, Guo P, Liu X. 2018. MALAT1: A long non-coding RNA highly associated with human cancers. Oncol Lett 16:19–26.PubMedPubMedCentral
25.
26.
go back to reference Hirata H, Hinoda Y, Shahryari V, Deng G., Nakajima K., Tabatabai Z.L., Ishii N., Dahiya R. 2015. Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. Cancer Res 75:1322–1331.CrossRef Hirata H, Hinoda Y, Shahryari V, Deng G., Nakajima K., Tabatabai Z.L., Ishii N., Dahiya R. 2015. Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. Cancer Res 75:1322–1331.CrossRef
27.
go back to reference Zhang R, Hardin H, Huang W, Chen J, Asioli S, Righi A, Maletta F, Sapino A, Lloyd RV 2017. MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR. Endocr Pathol 28:7–12.CrossRef Zhang R, Hardin H, Huang W, Chen J, Asioli S, Righi A, Maletta F, Sapino A, Lloyd RV 2017. MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR. Endocr Pathol 28:7–12.CrossRef
28.
go back to reference Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, Tassone P 2018. MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. J Hematol Oncol 11:63.CrossRef Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, Tassone P 2018. MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. J Hematol Oncol 11:63.CrossRef
29.
go back to reference Tang Q, Hann SS. 2018. HOTAIR: An Oncogenic Long Non-Coding RNA in Human Cancer. Cell Physiol Biochem 47:893–913.CrossRef Tang Q, Hann SS. 2018. HOTAIR: An Oncogenic Long Non-Coding RNA in Human Cancer. Cell Physiol Biochem 47:893–913.CrossRef
30.
go back to reference Ji S, Qin Y, Shi S, Liu X., Hu H., Zhou H., Gao J., Zhang B., Xu W., Liu J., Liang D., Liu L., Liu C., Long J., Zhou H., Chiao P.J., Xu J., Ni Q., Gao D., Yu X. 2015. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res 25:561–573.CrossRef Ji S, Qin Y, Shi S, Liu X., Hu H., Zhou H., Gao J., Zhang B., Xu W., Liu J., Liang D., Liu L., Liu C., Long J., Zhou H., Chiao P.J., Xu J., Ni Q., Gao D., Yu X. 2015. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res 25:561–573.CrossRef
31.
go back to reference Chang YT, Lin TP, Tang JT, Campbell M, Luo YL, Lu SY, Yang CP, Cheng TY, Chang CH, Liu TT, Lin CH, Kung HJ, Pan CC, Chang PC 2018. HOTAIR is a REST-regulated lncRNA that promotes neuroendocrine differentiation in castration resistant prostate cancer. Cancer Lett 433:43–52.CrossRef Chang YT, Lin TP, Tang JT, Campbell M, Luo YL, Lu SY, Yang CP, Cheng TY, Chang CH, Liu TT, Lin CH, Kung HJ, Pan CC, Chang PC 2018. HOTAIR is a REST-regulated lncRNA that promotes neuroendocrine differentiation in castration resistant prostate cancer. Cancer Lett 433:43–52.CrossRef
32.
go back to reference Chakravadhanula M, Ozols VV, Hampton CN, Zhou L, Catchpoole D, Bhardwaj RD. 2014. Expression of the HOX genes and HOTAIR in atypical teratoid rhabdoid tumors and other pediatric brain tumors. Cancer Genet 207:425–428.CrossRef Chakravadhanula M, Ozols VV, Hampton CN, Zhou L, Catchpoole D, Bhardwaj RD. 2014. Expression of the HOX genes and HOTAIR in atypical teratoid rhabdoid tumors and other pediatric brain tumors. Cancer Genet 207:425–428.CrossRef
33.
go back to reference Zhang R, Hardin H, Huang W, Buehler D, Lloyd RV. 2018. Long Non-coding RNA Linc-ROR Is Upregulated in Papillary Thyroid Carcinoma. Endocr Pathol 29:1–8.CrossRef Zhang R, Hardin H, Huang W, Buehler D, Lloyd RV. 2018. Long Non-coding RNA Linc-ROR Is Upregulated in Papillary Thyroid Carcinoma. Endocr Pathol 29:1–8.CrossRef
34.
go back to reference Hardin H, Helein H, Meyer K, Robertson S, Zhang R, Zhong W, Lloyd RV 2018. Thyroid cancer stem-like cell exosomes: regulation of EMT via transfer of lncRNAs. Lab Invest 98:1133–1142.CrossRef Hardin H, Helein H, Meyer K, Robertson S, Zhang R, Zhong W, Lloyd RV 2018. Thyroid cancer stem-like cell exosomes: regulation of EMT via transfer of lncRNAs. Lab Invest 98:1133–1142.CrossRef
35.
go back to reference Vijayvergia N, Boland PM, Handorf E, Gustafson KS, Gong Y, Cooper HS, Sheriff F, Astsaturov I, Cohen SJ, Engstrom PF 2016. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. Br J Cancer 115:564–570.CrossRef Vijayvergia N, Boland PM, Handorf E, Gustafson KS, Gong Y, Cooper HS, Sheriff F, Astsaturov I, Cohen SJ, Engstrom PF 2016. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. Br J Cancer 115:564–570.CrossRef
36.
go back to reference Kim ST, Lee SJ, Park SH, Park JO, Lim HY, Kang WK, Lee J, Park YS 2016. Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. J Cancer 7:1044–1048.CrossRef Kim ST, Lee SJ, Park SH, Park JO, Lim HY, Kang WK, Lee J, Park YS 2016. Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. J Cancer 7:1044–1048.CrossRef
37.
go back to reference Kyriakopoulos G, Mavroeidi V, Chatzellis E, Kaltsas GA, Alexandraki KI. 2018. Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms. Ann Transl Med 6:252.CrossRef Kyriakopoulos G, Mavroeidi V, Chatzellis E, Kaltsas GA, Alexandraki KI. 2018. Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms. Ann Transl Med 6:252.CrossRef
38.
go back to reference Yadav R, Kakkar A, Sharma A, Malik PS, Sharma MC. 2016. Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors. Scand J Gastroenterol 51:994–999.CrossRef Yadav R, Kakkar A, Sharma A, Malik PS, Sharma MC. 2016. Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors. Scand J Gastroenterol 51:994–999.CrossRef
39.
go back to reference Mukhopadhyay S, Dermawan JK, Lanigan CP, Farver CF. 2018. Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections. Mod Pathol https://doi.org/10.1038/s41379-018-0122-7. Mukhopadhyay S, Dermawan JK, Lanigan CP, Farver CF. 2018. Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections. Mod Pathol https://​doi.​org/​10.​1038/​s41379-018-0122-7.
41.
go back to reference Rosenbaum JN, Guo Z, Baus RM, Werner H, Rehrauer WM, Lloyd RV. 2015. INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms. Am J Clin Pathol 144:579–591.CrossRef Rosenbaum JN, Guo Z, Baus RM, Werner H, Rehrauer WM, Lloyd RV. 2015. INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms. Am J Clin Pathol 144:579–591.CrossRef
42.
go back to reference Tanigawa M, Nakayama M, Taira T, Hattori S, Mihara Y, Kondo R, Kusano H, Nakamura K, Abe Y, Ishida Y, Okabe Y, Hisaka T, Okuda K, Fujino K, Ito T, Kawahara A, Naito Y, Yamaguchi R, Akiba J, Akagi Y, Yano H 2018. Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor. Med Mol Morphol 51:32–40.CrossRef Tanigawa M, Nakayama M, Taira T, Hattori S, Mihara Y, Kondo R, Kusano H, Nakamura K, Abe Y, Ishida Y, Okabe Y, Hisaka T, Okuda K, Fujino K, Ito T, Kawahara A, Naito Y, Yamaguchi R, Akiba J, Akagi Y, Yano H 2018. Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor. Med Mol Morphol 51:32–40.CrossRef
43.
go back to reference Rooper LM, Bishop JA, Westra WH. 2018. INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors. Am J Surg Pathol 42:665–671.CrossRef Rooper LM, Bishop JA, Westra WH. 2018. INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors. Am J Surg Pathol 42:665–671.CrossRef
44.
go back to reference Xin Z, Zhang Y, Jiang Z, Zhao L, Fan L, Wang Y, Xie S, Shangguan X, Zhu Y, Pan J, Liu Q, Huang Y, Dong B, Xue W 2018. Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. Hum Pathol 79:151–159.CrossRef Xin Z, Zhang Y, Jiang Z, Zhao L, Fan L, Wang Y, Xie S, Shangguan X, Zhu Y, Pan J, Liu Q, Huang Y, Dong B, Xue W 2018. Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. Hum Pathol 79:151–159.CrossRef
45.
go back to reference Uri I, Grozinsky-Glasberg S. 2018. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin Diabetes Endocrinol 4:16.CrossRef Uri I, Grozinsky-Glasberg S. 2018. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin Diabetes Endocrinol 4:16.CrossRef
46.
go back to reference Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. 2010. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 139:742–753, 753.e741CrossRef Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. 2010. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 139:742–753, 753.e741CrossRef
Metadata
Title
In Situ Hybridization Analysis of Long Non-coding RNAs MALAT1 and HOTAIR in Gastroenteropancreatic Neuroendocrine Neoplasms
Authors
Ying-Hsia Chu
Heather Hardin
Jens Eickhoff
Ricardo V. Lloyd
Publication date
01-03-2019
Publisher
Springer US
Published in
Endocrine Pathology / Issue 1/2019
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-018-9564-1

Other articles of this Issue 1/2019

Endocrine Pathology 1/2019 Go to the issue